When a young couple in India plans their first pregnancy, a thalassemia carrier test is rarely on their checklist—yet it could be the most important test they ever take. India is home to roughly 30–45 million carriers of the beta-thalassemia gene, the largest carrier population in the world. Every year, approximately 9,000 to 10,000 children are born with thalassemia major, a severe blood disorder requiring lifelong transfusions or a bone marrow transplant to survive. Many of these births are entirely preventable through a simple blood test done before marriage or during pregnancy. This guide explains what thalassemia is, which tests detect it, how it is managed in India, and why screening your family matters.
What Is Thalassemia?
Thalassemia is an inherited blood disorder where the body produces abnormal or insufficient haemoglobin (Hb)—the protein in red blood cells that carries oxygen. Without normal haemoglobin, red blood cells are fragile, misshapen, and destroyed faster than the bone marrow can replace them. The result is chronic anaemia—a hallmark feature of all forms of thalassemia.
Thalassemia is a genetic condition, caused by mutations in the genes that encode the haemoglobin protein chains. It is not contagious and cannot be "caught" from another person.
Types of Thalassemia
There are two main types based on which haemoglobin chain is affected:
| Type | Gene Affected | Most Common In India |
|---|---|---|
| Beta-thalassemia | HBB gene (beta-globin chain) | Most prevalent; affects all regions |
| Alpha-thalassemia | HBA1/HBA2 genes (alpha-globin chain) | More common in South India, Odisha, tribal populations |
Beta-thalassemia exists in three forms depending on how many gene mutations are inherited:
- Thalassemia Minor (Trait/Carrier): One mutated copy inherited; person is a carrier. Usually no symptoms or only mild anaemia. This is the most common form in India—30–45 million carriers.
- Thalassemia Intermedia: Two mutations but with partial function. Moderate anaemia; may or may not need transfusions.
- Thalassemia Major (Cooley's Anaemia): Two mutated copies inherited; both HBB genes are non-functional. Severe anaemia starts in infancy; requires lifelong treatment.
How Is Thalassemia Inherited?
Thalassemia follows an autosomal recessive inheritance pattern:
- Two carrier parents have a 25% chance of having a thalassemia major child in each pregnancy
- Two carrier parents have a 50% chance of having a carrier child and a 25% chance of having a completely unaffected child
- If only one parent is a carrier, none of their children will have thalassemia major (though 50% may be carriers)
This is why premarital and prenatal screening is so critical—identifying carrier status before conception gives couples life-changing options.
Who Is at Risk in India?
While any Indian community can carry the thalassemia gene, certain ethnic groups and regions have significantly higher carrier rates:
| Community / Region | Approximate Carrier Rate |
|---|---|
| Sindhi (especially Kutchi Bhanushali, Lohana) | 5–17% |
| Punjabi Khatri and Arora | 5–7% |
| Bengali (Muslim and Hindu) | 5–7% |
| Gujarati communities | 4–8% |
| Tribal populations (Orissa, MP, Gujarat) | 4–10% |
| General Indian population average | 3–4% |
Regions with higher overall burden include Maharashtra, Gujarat, West Bengal, Punjab, Assam, and Karnataka—the same states where the ICMR's Jai Vigyan programme established dedicated thalassemia screening centres.
Recognising Thalassemia: Signs and Symptoms
Thalassemia Trait (Minor / Carrier)
Most carriers are completely healthy and have no symptoms. They may have:
- Mild anaemia (haemoglobin slightly lower than normal)
- Smaller-than-normal red blood cells (microcytosis) on a CBC report
- Slightly low MCV (Mean Corpuscular Volume) on the CBC
Many carriers discover their status only when a CBC done for a routine health check shows a low MCV—prompting their doctor to order a confirmatory HPLC test.
Thalassemia Major
Children with thalassemia major appear normal at birth but develop severe anaemia within the first 6–24 months of life as foetal haemoglobin (HbF) is replaced by defective adult haemoglobin.
Classic features in untreated or under-treated children:
- Severe pallor (pale skin and conjunctiva)
- Jaundice (yellowing due to excessive red cell breakdown)
- Hepatosplenomegaly: massively enlarged liver and spleen (the spleen tries to compensate by making blood cells)
- Failure to thrive: poor weight gain, growth retardation, delayed milestones
- Thalassaemic facies: frontal bossing (prominent forehead), maxillary hypertrophy (protruding upper jaw), and skull bossing—caused by the bone marrow expanding to compensate for inadequate blood production
- Bone pain and fragile bones
- Fatigue, irritability, and recurrent infections
With regular blood transfusions, most of these features are controlled and children grow relatively normally—though iron overload from transfusions becomes the next management challenge.
Diagnosing Thalassemia: The Tests You Need
Step 1: Complete Blood Count (CBC / Haemogram)
The CBC is the first clue. In thalassemia trait, look for:
- Low MCV (Mean Corpuscular Volume): typically <70–75 fL (normal: 80–100 fL)
- Low MCH (Mean Corpuscular Haemoglobin): <27 pg (normal: 27–33 pg)
- High RBC count with low haemoglobin — a distinctive pattern unlike iron deficiency, where RBC count is also low
- Mild anaemia (Hb typically 9–11 g/dL in carriers)
NESTROFT (Naked Eye Single Tube Red cell Osmotic Fragility Test) is a simple, low-cost screening test used at community health centres across India to flag potential thalassemia carriers before sending for confirmatory testing.
Step 2: HPLC (High-Performance Liquid Chromatography) — Gold Standard
HPLC is the definitive confirmatory test for thalassemia and other haemoglobinopathies. It precisely measures the proportions of different haemoglobin variants in the blood:
| Haemoglobin Fraction | Normal Adult | Beta-Thalassemia Trait | Beta-Thalassemia Major |
|---|---|---|---|
| HbA (adult) | 95–97% | 85–90% | <10% or absent |
| HbA2 | 1.5–3.5% | >3.5% (elevated) | Variable |
| HbF (foetal) | <1% | 1–5% | 30–90% |
A raised HbA2 above 3.5% is the hallmark finding confirming beta-thalassemia trait. HPLC costs approximately ₹500–₹1,500 at labs like Dr. Lal PathLabs, SRL Diagnostics, and Metropolis across India.
Step 3: Haemoglobin Electrophoresis
Hb electrophoresis separates different haemoglobin variants by their electric charge. It is used when HPLC is unavailable and can identify thalassemia, sickle cell disease (HbS), HbE (very common in Northeast India and West Bengal), and other variants. Increasingly, HPLC is replacing electrophoresis as the preferred test because it is more accurate and quantitative.
Step 4: Prenatal Diagnosis
When both parents are confirmed carriers, prenatal diagnosis during pregnancy can determine whether the foetus has thalassemia major:
- Chorionic villus sampling (CVS): Done at 10–13 weeks of pregnancy; provides foetal DNA for genetic testing
- Amniocentesis: Done at 15–18 weeks; foetal cells from amniotic fluid are analysed
- Pre-implantation genetic testing (PGT): During IVF, embryos are screened before implantation—an option for carrier couples who wish to avoid termination dilemmas
These tests are available at specialised fetal medicine centres and genetic labs in India, including AIIMS, CMC Vellore, and Tata Medical Centre Kolkata.
Managing Thalassemia Major in India
Regular Blood Transfusions
Children with thalassemia major require packed red blood cell transfusions every 2–4 weeks throughout their lives to maintain haemoglobin above 9–10 g/dL. Each transfusion session typically lasts 3–4 hours. Regular transfusions allow normal growth and development, prevent the skeletal deformities of untreated thalassemia, and enable children to attend school and lead relatively normal lives.
Key challenge: Every unit of transfused blood deposits approximately 200–250 mg of iron in the body. Since the human body has no mechanism to excrete excess iron, iron accumulates in the heart, liver, and endocrine glands—a condition called iron overload or haemosiderosis—which causes organ damage if untreated.
Chelation Therapy (Iron Removal)
Chelation therapy is the use of medications that bind to excess iron and allow it to be excreted through urine or stool. It is essential for all regularly transfused thalassemia patients.
Chelating agents used in India:
| Drug | Brand Name in India | Route | Cost (approx.) |
|---|---|---|---|
| Deferasirox | Asunra, Defrijet, Exjate | Oral (once daily dispersible tablet) | ₹1,200–₹2,500/month |
| Deferoxamine | Desferal | Subcutaneous pump (8–12 hrs/night) | ₹2,000–₹4,000/month |
| Deferiprone | Kelfer | Oral (three times daily) | ₹600–₹1,500/month |
Deferasirox (oral, once daily) has transformed adherence in India—particularly for children who struggled with the overnight deferoxamine pump. Serum ferritin should be checked every 3 months; a target ferritin below 1,000 ng/mL significantly reduces cardiac and liver complications.
You can use MedicalVault's trend analysis to track serial serum ferritin values, liver function tests, and echo reports over time—making it easier to share trends with the haematologist at each visit.
Bone Marrow (Stem Cell) Transplant — The Cure
A bone marrow transplant (BMT) or haematopoietic stem cell transplant (HSCT) is the only currently established cure for thalassemia major. The diseased bone marrow is replaced with healthy marrow from a matched donor, giving the patient the ability to produce normal haemoglobin permanently.
India's growing expertise: India has emerged as one of the leading countries for affordable thalassemia BMT, with excellent outcomes from centres including AIIMS Delhi, Tata Medical Centre Kolkata, Christian Medical College Vellore, Narayana Health Bangalore, and PGIMER Chandigarh.
Key facts about BMT for thalassemia in India:
- Best results in children under 7 years with low iron overload and good organ function
- Requires a matched sibling donor (HLA-matched brother or sister) for best results; haploidentical (half-matched parental) and matched unrelated donor transplants are also performed
- Cost: approximately ₹15–₹30 lakh at Indian centres—significantly lower than the ₹2–₹4 crore cost in Western countries
- Success rate: approximately 85–90% disease-free survival in low-risk children with matched sibling donors at experienced Indian centres
- Available through some state government schemes and Ayushman Bharat PM-JAY at empanelled centres for eligible families
Thalassemia Screening in India: What You Should Know
Premarital Screening
Several Indian states, including Maharashtra, Gujarat, and West Bengal, have initiated premarital thalassemia screening programmes. The Maharashtra government mandates thalassemia testing as part of pre-marital health certificates under specific schemes. If both individuals in a couple are found to be carriers, genetic counselling helps them understand their reproductive options.
Antenatal Screening
The National Health Mission (NHM) recommends routine haemoglobin testing in all pregnant women, but targeted thalassemia screening (HPLC/electrophoresis) is only systematically done in high-prevalence communities in most states. If you are pregnant and belong to a high-risk community (Sindhi, Punjabi, Gujarati, Bengali, or tribal populations), ask your obstetrician explicitly for an HPLC test—do not assume it is included in the routine antenatal panel.
National Thalassemia Control Programme
The ICMR's Jai Vigyan Mission on Thalassemia established a network of thalassemia screening and control centres across six states. The Federation of Indian Thalassemics (FIT) and Thalassemics India are prominent patient advocacy groups that maintain registries of treatment centres across the country and provide counselling support to families.
Storing and Tracking Thalassemia Reports
Managing thalassemia involves a lifetime of test results: serial CBC reports, serum ferritin values every 3 months, annual LFT and echocardiograms, HPLC results for family members, and prenatal genetic reports. Keeping these scattered across paper reports, WhatsApp messages, and hospital folders makes it nearly impossible to track trends over time.
MedicalVault's trend analysis helps thalassemia families track ferritin, haemoglobin, and liver function trends over months and years—so you and your haematologist always have the complete picture at a glance. The family sharing feature lets parents manage their child's records while also keeping track of carrier test results for siblings and other family members—all in one secure place.
Key Takeaways
- India has 30–45 million beta-thalassemia carriers—the world's largest carrier population; approximately 9,000–10,000 thalassemia major children are born here every year
- Thalassemia trait (carrier) causes no or minimal symptoms; it is identified by a low MCV on CBC and confirmed by HPLC showing elevated HbA2 >3.5%
- Thalassemia major causes severe anaemia from infancy and requires lifelong blood transfusions or a bone marrow transplant
- When both parents are carriers, each pregnancy carries a 25% risk of thalassemia major—premarital and prenatal screening can prevent this
- High-risk communities include Sindhis, Punjabi Khatris, Gujaratis, Bengalis, and tribal populations from Odisha, MP, and Gujarat
- Chelation therapy with oral deferasirox manages the iron overload from transfusions; serum ferritin should be tracked every 3 months
- Bone marrow transplant is the only cure and is available at ₹15–₹30 lakh at experienced Indian centres with excellent outcomes for low-risk children
- Use MedicalVault to track serial ferritin, CBC, and LFT trends for thalassemia patients and store carrier test results for the entire family